Prescribing information

 

_

Thalassaemia refers to a group of inherited blood disorders, including alpha-thalassaemia and beta-thalassaemia, characterised by decreased or absent synthesis of normal Hb globin chains in RBCs.1 This is caused by molecular defects in the alpha-globin gene cluster or the beta-globin gene cluster. The imbalance of these globin chains leads to ineffective RBC production, resulting in chronic haemolytic anaemia and low levels of oxygen in the blood.1

The total annual incidence of symptomatic individuals is estimated at 1 in 100,000 worldwide.2

Box listing the types of thalassaemia by the degree of transfusion dependence
Box listing the potential complications of untreated thalassaemia
 

Thalassaemia and the risk of iron overload1

In transfusion-dependent thalassaemia, iron overload is a consequence of repeated blood transfusions that are required to counteract the insufficient production of RBCs.

In non-transfusion-dependent thalassaemia, iron overload develops from increased intestinal iron absorption signalled by ineffective RBC production.

 

Abbreviation: RBC, red blood cell.

References

  1. Taher AT and Saliba AN. Iron overload in thalassemia: different organs at different rates. Hematology Am Soc Hematol Educ Program. 2017;2017(1):265–271.
  2. Galanello R and Origa R. Beta-thalassemia. Orphanet J Rare Dis 2010;5:11.
HCP20-C005r June 2020.

 

For more information, refer to the EXJADE® (deferasirox) Summary of Product Characteristics:
https://www.medicines.org.uk/emc/product/7775/smpc.

Legal Category: POM.

PVC/PVDC/Aluminium blisters. Unit packs containing 30 or 90 film-coated tablets or multipacks containing 300 (10 packs of 30) film-coated tablets. Not all pack sizes may be marketed. Marketing Authorisation (MA) number, quantities and NHS price: EU/1/06/356/011 – 90 mg film-coated tablets 30 pack, £126.00. EU/1/06/356/014 – 180 mg film-coated tablets 30 pack, £252.00. EU/1/06/356/017 – 360 mg film-coated tablets 30 pack, £504.00 pack £1,540, EU/1/10/612/008 – 75 mg x 28 tablet pack £2,310.

 

 

For more information, refer to the DESFERAL® (desferrioxamine mesilate) Summary of Product Characteristics:
https://www.medicines.org.uk/emc/product/3813#PHARMACEUTICAL_PARTS.

Legal Category: POM.

Each vial contains a white to practically white lyophilisate supplied in a clear glass vial in a pack size of 10 (500 mg) or 1 (2 g). Marketing Authorisation (MA) number, quantities and NHS price: PL 00101/0523. Boxes of 10 £46.63.

 

×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the patient safety information (PSI) tool at https://psi.novartis.com
If you have a question about the product, please contact Medical Information on 01276 692255 or by email at [email protected]